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Sresults often show increased localized haziness at the treated segment that is attributable to
multiple intimal ﬂaps, dissection and atheromatous tissues. We analyzed the safety,
focused on the rates of acute thrombosis after DCB in de-novo lesions without additional
stenting (the so called drug-eluting balloon only strategy) in a clinical setting.
Methods: A retrospective review was done of 191 consecutive patients who under-
went percutaneous coronary intervention procedure with the paclitaxel eluting balloon
SeQuent Please at a high-volume Heart Center in Potsdam. DCB was used for the
treatment of de-novo lesions in 85 patients (male n¼61, age 67.1  10.9 years) in 102
interventions. Interventions included small coronary arteries, long lesions, ostial
lesions and bifurcation lesions. All patients were pretreated with aspirin and clopi-
dogrel/prasugrel (DAPT), which was continued for at least 4 weeks.
Results: A localized haziness at the treated segment was found in 17 interventions
(16.8%).Duringhospital staynoneof the 85patients (0%)hadsuffered fromacute coronary
thrombosis in the clinical setting. Unscheduled coronary angiography was performed in
one patient (1%) within 72 hours after DCB because of recurrent chest pain and showed an
excellent short-term result with TIMI III ﬂow and without need for revascularization.
Conclusions: Incidence of localized haziness after DCB angioplasty in de-novo
lesions is comparable to treatment with plain old balloon angioplasty and does not
increase the risk of acute coronary thrombosis.
TCT-459
Incidence of late thrombosis after paclitaxel-coated balloon angioplasty in de-
novo coronary artery disease
Theresa Weichert1, Annette Fengler1, Philip Steen1, Klaus Bonaventura1
1Klinikum Ernst von Bergmann, Potsdam, Germany
Background: Clinical studies demonstrated the safety and effectiveness of drug-
coated balloon (DCB) in various clinical scenarios and support the use of paclitaxel-
eluting balloon for the treatment of in-stent restenosis, of small coronary arteries and
bifurcation lesions. We analyzed and compared the safety, focused on the rates of late
coronary thrombosis (LT), after DCB in de-novo lesions without additional stenting -
the so called "Drug-eluting balloon only" strategy - in four current studies with the
outcome in a clinical setting.
Methods: A retrospective review was done of 191 consecutive patients who under-
went percutaneous coronary intervention procedure with the paclitaxel eluting balloon
SeQuent Please at a high-volume Heart Center in Potsdam. DCB was used for the
treatment of de-novo lesions in 85 patients (male n¼61, age 67.1  10.9 years) in 102
interventions. The primary evaluation was LT. Mean clinical follow-up was 16.3 
5.5 months. Duration of dual antiplatelet therapy was 5.4  4.1 months.
Results: DCB without additional stenting was used in different clinical and interven-
tional settings. During follow-up none of the 85 patients (0%) had suffered from late
coronary thrombosis in the clinical setting. This is remarkable since DCB were mostly
used in complex interventions. Three patients died due to renal failure, one of them after
elective cardiac surgery and one patient died due to non-cardiovascular disease. Four
DCB trials used the "Drug-eluting balloon only" strategy in de-novo lesions: PEPCAD I
SVD, PEPCAD V (side branch), PICCOLETO and DEBUIT. Summarizing the rates of
LT after 6 to 12 months LT was reported in none of the 179 patients (0%).
Conclusions: The use of DCB in de-novo coronary artery disease is not associated
with a higher rate of LT. Beside the proven efﬁcacy the possible reduction in the
duration of DAPT to one month may represent additional advantages regarding safety,
patient compliance and costs for the Drug-eluting balloon only strategy. Further larger
scale studies are needed before DCB can be recommended for routine initial use in all
cases as an alternative approach.
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Magnitude of Stent Expansion Inﬂuences Local In-Stent Hyperplasia and Lumen
Changes Following Stent Implantation in Humans
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Background: In-stent restenosis (ISR) remains as a limitation of percutaneous
coronary intervention (PCI). Post-implantation stent expansion assessed by intravas-
cular ultrasound (IVUS) has been used to optimize PCI outcomes, but there are limited
data regarding on the effect of local stent expansion on ISR. The objective of this
study was to assess the relationship between local stent expansion and in-stent
hyperplasia (ISH) and lumen loss.
Methods: Vascular proﬁling (3-vessel 3D coronary reconstruction by angiography &
IVUS) was performed in 374 patients at baseline (BL) & 6-10 months follow-up (FU).
Each reconstructed coronary artery was divided into 1.5-mm segments for serial study.
A total of 80 bare-metal stents (BMS), 51 sirolimus-eluting stents (SES) and 25
paclitaxel-eluting stents (PES) were analyzed. At baseline, local stent expansion was
deﬁned as the ratio of stent area to the respective reference lumen area. Stent
expansion ratio was categorized as underexpansion (stent expansion <0.8), normal
(stent expansion 0.8-1.2) and overexpansion (stent expansion > 1.2).
Results: ISH area in overexpansion group is signiﬁcantly larger than in under-
expansion group at FU (3.3  2.0 mm2 vs 2.0  1.4 mm2, p<0.001 in BMS; 0.33 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstr0.53 mm2 vs 0.0036  0.028 mm2, p<0.001 in SES; and 0.71  0.78 mm2 vs 0.44 
0.42 mm2, p¼0.014 in PES). There was signiﬁcant lumen area decrease in over-
expansion group at FU compared to underexpansion group in all stent types (delta¼
3.3  2.0 mm2 vs 0.61  2.3 mm2, p<0.001 in BMS; delta¼ 0.55  1.5 mm2 vs -1.7
 1.6 mm2, p<0.001 in SES; and delta¼ 1.2  1.2 mm2 vs -0.52  1.1 mm2,
p<0.001 in PES). Lumen area in overexpansion group in SES became smaller than in
underexpansion group (8.1  1.5 mm2 vs 9.2  3.0 mm2, p¼0.01 in SES). In BMS
and PES, the relationship in lumen area at FU between overexpansion and under-
expansion groups were similar (8.7  2.5 mm2 vs 9.0  4.6 mm2, p¼0.58 in BMS;
8.1  1.2 mm2 vs 7.7  1.8 mm2, p¼0.12 in PES).
Conclusions: Overexpanded stent segment showed greater ISH and lumen loss at FU
regardless of stent type. There is less advantage of aggressive dilation at stent
deployment to get larger lumen.
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Isolated Left-Anterior-Descending Artery In-stent Restenosis: Comparison
Between Treatment With PCI-DES And CABG With Left-Internal-Mammary
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Dennis Zavalloni1, Margherita Soldi2, Giuseppe Ferrante1, Marco G. Mennuni1,
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Background: The treatment of isolated in-stent restenosis (ISR) of the left-anterior-
descending artery (LAD) can be performed either with PCI with drug-eluting sten-
t(DES) or with surgical bypass with left-internal-mammary artery(LIMA). So far, no
data are available on the comparison between these two revascularization techniques
in this particular clinical context.
Methods: We compared clinical outcomes (MACCE:Major adverse cardiac cere-
brovascular events and procedure-related complications)of PCI with DES(DES group)
to surgery with LIMA(CABG group)for the treatment of pts with isolated LAD-
ISR.Continuous and categorical data were compared with t-Student and X2-test,res-
pectively.Kaplan-Meier method was used for comparisons during follow-up whereas
Cox-regression analysis to assess predictors of new revascularizations.
Results: We enrolled 141 consecutive patients with isolated LAD-ISR:70 pts in
PCI group and 71 pts in CABG group.The two groups were well-matched for
clinical characteristics. DES-ISR was present in 79% and BMS-ISR in 21% of
cases in the PCI group,while DES-ISR was found in 21% and BMS-ISR in 79% in
the CABG group(p<0.001).A 3-year clinical follow-up was achieved in>90%.
MACCE were observed in 22.8% of pts in PCI group and 30.9% in CABG group
(log-rank p ¼0.38).Target-lesion revascularization(TLR) was observed in 8.5% pts
in the PCI group whereas LIMA failure in 8.4% of the CABG group (P¼0.9).Non-
Target vessel revascularization occurred in 8.6 % and 14.1% of patients in the PCI
and CABG group,respectively (p¼0.22).At multivariable Cox-regression analysis,
predictors of any revascularization were chronic renal failure(HR 1.32; 95%CI
1.09-1.59),LDL-cholesterol levels(HR 1.29; 95%CI 1.09-1.51)and HbA1c levels
(HR 1.59; 95%CI 1.0-1.90). When compared with PCI group, CABG group was
characterized by higher rates of in-hospital complications/need for transfusion
(1.4% vs 28.1%, p<0.0001) and length of hospitalization (2.1 vs 5.7 days,
p<0.0001)
Conclusions: Isolated LAD-ISR may be effectively treated either PCI with DES and
CABG with LIMA. However, CABG treatment is characterized by higher rates of in-
hospital complications and requires longer hospitalization.
TCT-462
The difference in Temporal Change of Peri-stent Contrast Staining Between
Drug-eluting Stent and Bare-metal Stent
Takeshi Tada1, Kazushige Kadota1, Seiji Habara1, Hiroyuki Tanaka1, Yasushi Fuku1,
Tsuyoshi Goto1, Kazuaki Mitsudo2
1Kurashiki Central Hospital, Kurashiki, Japan, 2Kurashiki Central Hospital,
Okayama, Japan
Background: It was reported that peri-stent contrast staining (PSS) was one of
abnormal vessel reactions including incomplete stent apposition assessed with optical
coherence tomography. Little is known about the differences in temporal change of
PSS among various stents.
Methods: Between October 2001 and February 2012, percutaneous coronary inter-
vention was performed with bare-metal stent (BMS) in 2138 lesions and with drug-
eluting stent (DES) in 11138 lesions. We routinely performed follow-up coronary
angiography (CAG) at 6th and 18th month after BMS implantation and 8th and 20th
month after DES implantation, and found PSS in 56 lesions with BMS and 281 lesions
with DES (2.62% vs. 2.52%, p¼0.764). The temporal change of PSS between 6-8 and
18-20 months after stent implantation was conﬁrmed with CAG in 36 lesions with
BMS and 191 lesions with DES, which were classiﬁed into 3 groups: progressive,
unchanged, and regressive PSS. We examined the difference in temporal change of
PSS between DES and BMS. Furthermore, the temporal change after the 20th month
of stent implantation was examined with unscheduled CAG in 9 BMS lesions and 53
DES lesions. DES were classiﬁed into SES and non-SES.
Results: The results are shown in the ﬁgure. Progressive PSS after 20th month of stent
implantation was observed only in 9 of 43 lesions (20.9%) after SES implantation.acts/POSTER/In-stent Restenosis and Stent Thrombosis B141
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SConclusions: Temporal change of PSS might be different between SES, non-SES, and
BMSuntil the 20thmonth of stent implantation.After the 20thmonth of stent implantation,
abnormal vessel reactions appeared to continue in some lesions after SES implantation.
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Impact of Late Catch-up Phenomenon on Delayed Restenosis After Sirolimus-
Eluting Stent and Bare-Metal Stent Implantation
Kenji Sakata1, Yuki Horita2, Naoto Tama2, Toshimitsu Takagi2, Isao Inoki2,
Hedenobu Terai2, Masatoshi Ikeda2, Masanobu Namura2, Masakazu Yamagishi1
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Cardiovascular Hospital, Kanazawa City, Ishikawa Prefecture
Background: There are limited data on whether delayed late catch-up exists in
sirolimus-eluting stents (SES) and bare-metal stents (BMS). We sought to compare
differences in time course of late loss (LL) between SES and BMS.
Methods: Serial (8-months, 2-years, and over 3-years) angiographic examination was
performed in 598 lesions treated with SES (n¼353) or BMS (n¼245). Lesions with 8-
months and 2-years instent-restenosis (>50% of angiographic diameter stenosis) were
excluded. LL was categorized as early (between post-procedure and 8-months),
delayed (between 8-months and 2-years), further delayed (between 2-years and over 3-
years) or overall (between post-procedure and over 3-years).
Results: Whereas early LL was signiﬁcantly smaller in SES than in BMS, delayed LL
was signiﬁcantly greater in SES than in BMS. On the other hand, further delayed LLwas
comparable between the 2 stents. Consequently, overall LL was signiﬁcantly smaller in
SES than in BMS. Moreover, the incidence of over 3-year instent-restenosis was similar
between the 2 stents (1.13 and 0.82% in SES and BMS, p¼0.70). In multivariate
analysis, stent type predicted delayed LL but did not predict further delayed LL.
Conclusions: SES lumen diameter progressively narrowed in delayed phase
compared with BMS. However, the narrowing rate was similar among SES and BMS
over 2 years. This evidence may raise the possibility that the impact of late catch-up
phenomenon on SES restenosis over 2 years is minimal.TCT-464
Comparison of Cutting Balloon Angioplasty for the Treatment of Restenosis with
Bare Metal Stent; Neointimal Hyperplasia Tissue vs Neoatherosclerosis tissue
Maoto Habara1, Kenya Nasu2, Takahiko Suzuki1, Mitsuyasu Terashima1
1Toyohashi Heart Center, Toyohashi, Japan, 2Toyohashi Heart Center, Toyohashi, Aichi
Background: The morphological characteristics of restenotic tissue with bare metal
stent (BMS) in very late in-stent restenosis (VL-ISR) were different from those in early
in-stent restenosis (E-ISR) and similar to atherosclerotic plaque which is called neo-
atherosclerosis. However, the efﬁcacy of cutting balloon angioplasty (CBA) for those
different tissues has not been analyzed. The purpose of this study is to compare the
efﬁcacy of CBA for ISR of BMS according to the morphologic pattern of restenosis.
Methods: Patients with ISR of BMSwere enrolled and were performed optical coherence
tomography before intervention. According to the optical coherence tomography (OCT)
images and periods after stent implantation, those patients were categorized to 2 group; 1)
Neoatherosclerosis group (n¼38); angiographcial restenosiswas revealed later than5 years
after stent implantation without restenosis within the ﬁrst year and lipid-like image was
shown by OCT image; 2) neointimal hyperplasia (NIH) group (n¼62); angiographical
restenosis was revealedwithin ﬁrst year andOCT image showed homogeneous intima. All
cases were treated with CBA and 6months follow-up angiography was performed and the
angiographic ﬁndings at 6 months follow-up were compared between the 2 groups.
Results: At 6 months angiographic follow-up, the frequency of re-ISR and target
lesion revascularization were signiﬁcantly higher in neoatherosclerosis group (57.8%
vs 35.4%, 44.7% vs 24.2%; p<0.05). Re-occlusion was revealed only 1 case in
neoahterosclerosis group (p¼0.31). There was no signiﬁcant differences about late
loss (0.870.56mm vs 0.740.75mm, p¼0.39).
Conclusions: The treatment with CBA for BMSVL-ISR lesion with neoatherosclesosis
could not show similar efﬁcacy compare to those for BMSE-ISR lesion with NIH tissue.B142 JACC Vol 62/18/Suppl B j October 27–November 1, 20TCT-465
Drug-Eluting Balloon in the Treatment of Instent Restenosis and Diffuse
Coronary Artery Disease; Real World Experience from a Single Center Registry
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1Imperial College, London, London, 2San Raffaele Scientiﬁc Institute, Milan, Italy,
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Background: Although stents form the backbone of PCI, they may not be ideal
for all lesions, especially; in-stent restenosis (ISR) and diffuse disease in small
vessels. Drug-eluting balloons (DEB) are emerging as an alternative treatment in
such situations and their use is escalating. DEBs have been studied in randomized
trials and registry studies with favourable outcomes. Despite these studies, data
from real-world population is lacking. We report a single-center experience of
DEB in the treatment of ISR and de novo coronary artery disease from a large
cohort of patient.
Methods: We retrospectively evaluated all patients treated with the drug-eluting
balloon (In.Pact FalconTM, Medtronic Inc., Minneapolis, MN, USA) between January
2009 and December 2011. The measured endpoints were cardiac death, MI, target
lesion revascularization (TLR), target vessel revascularization (TVR) and major
adverse cardiac events (MACE) deﬁned as combination of cardiac death, MI and
TVR.
Results: A total of 7622-PCI procedures were carried out at our centre during the
study period. Drug-eluting balloons were used in 275-lesions (184-patients) (3.6%).
The predominant indication for DEB use was ISR (n¼170, 62%), with de novo lesions
accounting for the remainder (n¼105, 38%). The mean age of patients treated with
DEB was 66.29.6 years and 87% were male. Bailout stenting was required in 31.6%
of lesions; 24% for angiographic optimization and 7.3% for dissection caused by
balloon injury. The median clinical follow-up was 14.6 months (IQR 12-23) and
a minimum of 6-months follow-up was achieved in all patients. The rates of cardiac
death, MI, TLR, TVR and MACE were: 3.8%, 1.6%, 16.8%, 17.9% and 21.7%
respectively. The overall rate of stent thrombosis was 0.5% (n¼1). Further sub-
analysis revealed that the beneﬁts of DEB use were more pronounced in BMS-ISR
than DES-ISR (TLR: 11% vs. 17.7%, TVR: 11% vs. 22%, MACE: 15% vs. 28%)
respectively.
Conclusions: Our results suggests that DEB can be considered in lesions where the
use of stents are not desirable especially restenotic lesions and diffuse small vessel
disease. Further long-term follow-up of these patients, will provide us more insights
on the long-term outcomes.
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Paclitaxel-coated Balloon Versus Drug-eluting Stent for the Treatment of
In-stent Restenosis in Patients with Renal Failure on Hemodialysis
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Kazushige Kadota2, Kazuaki Mitsudo3, Suguru Otsuru2, Yoshikazu Shigemoto2,
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Background: It has not been reported about the efﬁcacy of paclitaxel-coated balloon
for in-stent restenosis in patients with renal failure on hemodialysis.
Methods: From January 2003 to August 2012, 359 in-stent restenosis lesions in
patients with renal failure on hemodialysis underwent percutaneous coronary inter-
vention. One hundred sixty one lesions (56 lesions treated with paclitaxel-coated
balloon, 105 lesions treated with drug-eluting stent) underwent midterm follow-up
coronary angiography by 8 months after treatment. We compared the quantitative
coronary analysis data and the rates of restenosis and target lesion revascularization
(TLR) at midterm f/u between paclitaxel-coated balloon group and drug-eluting stent
group.
Results: There were no signiﬁcant difference in the rates of restenosis and TLR. The
minimal luminal diameter at midterm f/u showed no signiﬁcant difference between
two groups, but the late loss was signiﬁcantly small in paclitaxel-coated balloon
group. Data are shown in the table.
Conclusions: The treatment with paclitaxel-coated balloon has the equivalent efﬁcacy
of treatment with drug-eluting stent for in-stent restenosis in patients with renal failure
on hemodialysis.13 j TCT Abstracts/POSTER/In-stent Restenosis and Stent Thrombosis
